Introduction: Auto-immune and auto-inflammatory disorders are believed to cause approximately 20% of cases of pyrexia of unknown origin. Rheumatological opinion is often sought when an infectious source has not been detected. Assessment of recurrent fever is challengingforfear of initiating immunosuppression inthe presenceof undetected infection. This challenge is even greater in patients with a previous history of auto-immune orinfectious disorders. Here, we discuss the investigation and management of a challenging case of recurrent fever, ultimately diagnosed as adult-onset Still's disease, complicated bythe previous occurrenceof pulmonary tuberculosis and myastheniagravis. Case description: Our 34-year-old female patient, originally from India, had lived in the UK for 8 years. Her background included previous treatment for pulmonary TB in 2011 and myasthenia gravis diagnosed in 2015 with subsequent thoracoscopic thymectomy in 2016. She was admitted to the infectious diseases unit in October 2016 with 3 weeks of recurrent fever and an itchy rash which had commenced 1-week after holidaying in Spain. Pyrexiae were quotidian, occurring nocturnally and would usually last 1 hour with associated malaise and tachycardia. The rash affected the upper arms, buttocks and face but was not consistent in appearance; initially urticarial and later described as maculopapular. Polyarthralgia of the jointsof the hands was reported. Extensive infection screening including blood cultures and serology was negative. A CT-CAP revealed changes of old TB and borderline axillary lymphadenopathy. Immunology revealed a negative ANA and ENA screen along with normal levels of anti-PR3, MPO, DsDNA and CCP antibodies. Further investigations included a CRP of 213, ESR of 75 and serum ferritin of 450mcg/l . A provisional diagnosis of a periodic fever syndrome was made and the patient agreed to a trial of anti-interleukin 1 therapy (Anakinra 100mg SC OD) while awaiting genetic testing. Immediate defervescence of fever occurred with an improvement in the rash and dramatic reductionin inflammatory indices. Two months later the patient represented with malaise, tachycardia, periorbital odema, widespread rash, diarrhoea and a marked peripheral eosinophilia (5.69 x10 9 /L). Skin biopsy demonstrated vacuolar inflammation and prominent eosinophils. A diagnosis of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome was made and anakinra was withdrawn. However, the patient's condition deteriorated with a rebound elevation in inflammatory markers, pyrexia and development of synovitis. Repeat serum ferritin during this period was recorded at > 40,000mcg/ml and a diagnosis of adult-onset Still's disease was made. Discussion: This case was challenging on two particular fronts. Firstly, the arrival of a confident and definitive diagnosis was difficult. On initial review and again on deterioration 2 months later, the patient's previous history of TB, recent travel history and presence of lymphadenopathy led to significant concern of an alternative primary diagnosis. A large number of investigations for occult infection (e.g. TB recurrence) and malignancy (e.g. lymphoma) were conducted. Likewise, the absence of a history of a sore throat, the atypical skin rash, a very modest elevation in serum ferritin, and the absence of synovitis made adult-onset Still's disease less likely. However, the rapidity and magnitude of the response to Interleukin-1 inhibition with anakinra supported our suspicion of an autoinflammatory syndrome. The second hurdle in this case was the problematic pharmaceutical management once adult-onset Still's disease was diagnosed. The occurrence of DRESS syndrome secondary to anakinra is not something we had previously experienced nor does it appear to have been reported in the literature before despite a relatively high incidence of anaphylaxis and localized skin reactions with anakinra. Subsequent interleukin-6 blockade with tocilizumab was partially effective in improving symptoms and clinical parameters but did lead to significant derangement in liver function tests and treatment was stopped. There was an incomplete response to TNF-a inhibition with weekly subcutaneous etanercept injections in combination with high dose oral corticosteroids. Subsequently there was a good response to the monoclonal antibody canakinumab (anti-IL-1b). Our patient remains on 10mg of oral prednisolone but has largely remained in remission for 18 months in combination with canakinumab. Remaining concerns relate to thelong-termefficacyofcanakinumabforthis patientandthelimitedtherapeutic options if recurrent relapses occur. Furthermore, the risk of TB reactivation remains an unavoidable risk with ahighdegreeof clinical suspicion required. Key learning points: This was a challenging case complicated by the patient's past medical history of TB, myasthenia gravis and thymoma, in addition to the occurrence of DRESS syndrome which led to a period of diagnostic uncertainty. While the input of many specialties (i.e., respiratory, infectious diseases, haematology, and dermatology) were required and critical to the overall management of the patient, extensive and prolonged investigation can lead to significant delays in treatment. In such situations, an open discussion with the patient as to the risks and benefits of delaying treatment versus pursuing further investigation is advised. Furthermore, we have learnt from this case to appreciate that focused repetition of some investigations, in the setting of diagnostic uncertainty, can be beneficial. In this case repetition of serum ferritin levels, skin biopsy and cross-sectional CT imaging all led to important diagnostic conclusions and decisions that ultimately resulted in the correct diagnosis and successful management of this patient.
Conflict of interest:
The authors declare no conflicts of interest. Introduction: Adult-onset Still's disease (AOSD) is a rare inflammatory disorder of unknown aetiology with systemic involvement. The presentation and severity is highly variable in affected individuals and requires a clinical diagnosis, commonly using the Yamaguchi classification criteria. The majority of patients with AOSD develop non-specific symptoms associated with a systemic inflammatory response including fever, rash and arthralgia; however, a few patients with AOSD develop life-threatening complications. Here, we describe a case of newly diagnosed AOSD who rapidly deteriorated with myo-pericarditis, cardiogenic shock and multi-organ failure requiring ECMO, despite treatment with high dose oral corticosteroids. Case description:A 27-year oldfemalepresentedwitha6-monthhistory of joint pain, fever, sore throat, evanescent red rash, night sweats and weight loss. On examination she had florid synovitis in most of her small and large joints. Laboratory tests showed a DAT positive (IgG positive) haemolytic anaemia with haemoglobin 60g/L, raised ESR 98mm/hr and CRP 261mg/L and an elevated Ferritin level of 14,892ug/L. ANA, dsDNA and RF were negative; anti-cardiolipin IgM was initially positive, but negative on repeat. CT scan of the chest, abdomen and pelvis (CTCAP) showed diffuse lymphadenopathy, hepatomegaly and mild pericardial effusion. A likely diagnosis of AOSD was made and she rapidly improved clinically and biochemically on oral prednisolone 60mg daily. Her ferritin fell to5,500ug/Land shewas discharged with outpatient follow-up. 2-weeks later she re-presented feeling non-specifically unwell with new orthopnoea. She was tachycardic (HR 120bpm), hypotensive (BP 95/ 60mmHg), ECG showed widespread ST depression and she had significant hyperferritinaemia (50,695ug/L) with a raised Troponin-T level of 134ng/L. Despite treatment with intravenous methylprednisolone (IVMP) 1000mg, she rapidly deteriorated and 6-hours later had a brief period of cardiac arrest. Echocardiogram showed global hypokinesis and severe systolic dysfunction with ejection fraction of 15%. She had developed anuric renal failure, hyperlactataemia (Lactate 16) and profound shock in the setting of severe acute heart failure, and was started on VA-ECMO. Alongside supportive therapies this patient received 3 days of IVMP 1000mg/day, intravenous immunoglobulin (IVIg) 2mg/kg and intravenous anakinra 200mg daily. She made an excellent recovery -she was de-cannulated from VA-ECMO on day 4 and extubated on day 6. Ferritin level fell to 6439ug/L and troponin-T down to 64 ng/L. Due to hypoperfusive injury, the patient developed necrotic foot ulcers which required ORAL PRESENTATIONS 26 September 2019 i5 V C The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
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